Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts ≥200 cells/mm3

Antiviral Therapy

Volumn 12, Issue 6, 2007, Pages 941-947

  Lapadula, Giuseppe ^a   Torti, Carlo ^a   Maggiolo, Franco ^b   Casari, Salvatore ^c   Suter, Fredy ^b   Minoli, Lorenzo ^d   Pezzoli, Chiara ^a   Di Pietro, Massimo ^e   Migliorino, Guglielmo ^f   Quiros Roldan, Eugenia ^a   Ladisa, Nicoletta ^g   Sighinolfi, Laura ^h   Costarelli, Silvia ^a   Carosi, Giampiero ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c SPEDALI CIVILI   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^f OSPEDALE DI CIRCOLO   (Italy)

^g POLICLINICO   (Italy)

^h S ANNA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROGNOSIS;

EID: 34848830497     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378-384.
2. Wang C, Vlahov D, Galai N, et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004; 190:1046-1054.
3. Sterne J, May M, Costagliola D, et al. Estimating the optimum CD4 threshold for starting HAART in antiretroviral naïve HIV-infected individuals. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 525.
4. Sterling T, Chaisson R, Keruly J, Moore R. Improved outcomes with earlier initiation of HAART: longer follow-up of an observational cohort study. 10th Conference on Retroviruses and Opportunistic Infections. 10-14 February 2003; Boston, MA, USA. Abstract 570.
5. Shafran SD. Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2007; 44:551-556.
6. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19:221-240.
7. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55.
8. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7:487-503.
9. Phillips A. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004; 18:51-58.
10. Philips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD. When should antiretroviral therapy for HIV be started? BMJ 2007; 334:76-78.
11. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17):1- 19.
12. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
13. Panel on Clinical Practice for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 10, 2006; 1-113. Last accessed: 1st December 2006. Available from: http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentsGL.pdf
14. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
15. Raffanti SP, Fusco JS, Sherrill BH, et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr 2004; 37:1147-1154.
16. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-686.
17. + cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. HIV Clin Trials 2005; 6:127-135.
18. d'Arminio MA, Sabin CA, Phillips A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005; 165:416-423.
19. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-2577.
20. Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE Collaboration). Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts? J Acquir Immune Defic Syndr 2001; 28:158-165.
21. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
22. Centro Operativo AIDS.Istituto Superiore di Sanità. Aggiornamento dei casi di AIDS notificati in Italia e delle nuove diagnosi di infezione da HIV. [Operational AIDS Centre National Institutes of Health]. Last accessed: Aug 15, 2006. Available from: http://www.iss.it/binary/pres/cont/ Rap%20AIDS%2031%20Dicembre%202004.1129713087.pdf. Italian.
23. + T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001. J Acquir Immune Defic Syndr 2003; 33:380-386.
24. + cell counts: a EuroSIDA study. J Infect Dis 2006; 194:633-641.
25. 3 reach same mortality rates as general population: APROCO and Aquitane Cohorts, France. 10th European AIDS Conference/EACS. 17-20 November 2006; Dublin, Ireland. Abstract PE 18.4/8.